Long COVID Immunotherapy
Treatment of Long COVID / Post-Acute Sequelae of SARS-CoV-2 (PASC)
Pre-clinicalActive
Key Facts
Indication
Treatment of Long COVID / Post-Acute Sequelae of SARS-CoV-2 (PASC)
Phase
Pre-clinical
Status
Active
Company
About TechImmune
TechImmune is a private, preclinical-stage biotech developing T-cell-focused therapies for coronavirus infections, with a primary goal of creating a treatment for Long COVID. The company is built on a platform technology licensed from UC Irvine, aiming to clear persistent viral reservoirs and restore immune function. It is led by a highly experienced team with deep expertise in vaccine development and pharmaceutical commercialization and has been funded through private equity, NIH grants, and university partnerships. TechImmune is targeting a significant unmet medical need with substantial economic implications, estimated at $1 trillion annually.
View full company profile